CHAPTER 1 METHODOLOGY
1.1 MARKET DEFINITION
1.2 BASE ESTIMATES & CALCULATIONS
1.3 FORECAST PARAMETERS
1.4 COVID-19 IMPACT ANALYSIS AT GLOBAL LEVEL
1.5 DATA VALIDATION
1.6 DATA SOURCES
1.6.1 PRIMARY
1.6.2 SECONDARY
1.6.2.1 PAID SOURCES
1.6.2.2 PUBLIC SOURCES
CHAPTER 2 EXECUTIVE SUMMARY
2.1 ANTI-INFLAMMATORY DRUGS INDUSTRY 3600 SYNOPSIS, 2018 – 2032
2.1.1 BUSINESS TRENDS
2.1.2 REGIONAL TRENDS
2.1.3 DRUG CLASS TRENDS
2.1.4 TREATMENT TRENDS
2.1.5 ROUTE OF ADMINISTRATION TRENDS
2.1.6 SALES CHANNEL TRENDS
CHAPTER 3 ANTI-INFLAMMATORY DRUGS INDUSTRY INSIGHTS
3.1 INDUSTRY ECOSYSTEM ANALYSIS
3.2 INDUSTRY IMPACT FORCES
3.2.1 GROWTH DRIVERS
3.2.1.1 RISING PREVALENCE OF INFLAMMATORY DISEASES
3.2.1.2 INCREASING ADVANCEMENTS IN ANTI-INFLAMMATORY DRUGS DEVELOPMENT
3.2.1.3 RISING INCIDENCES OF AUTOIMMUNE DISEASE AND RESPIRATORY CONDITIONS
3.2.1.4 GROWING GERIATRIC POPULATION
3.2.2 INDUSTRY PITFALLS & CHALLENGES
3.2.2.1 STRINGENT REGULATORY APPROVAL
3.2.2.2 SIDE EFFECTS ASSOCIATED WITH ANTI-INFLAMMATORY DRUGS
3.3 GROWTH POTENTIAL ANALYSIS
3.3.1 BY DRUG CLASS
3.3.2 BY TREATMENT
3.3.3 BY ROUTE OF ADMINISTRATION
3.3.4 BY SALES CHANNEL
3.4 COVID- 19 IMPACT ANALYSIS
3.5 REGULATORY LANDSCAPE
3.6.1 U.S.
3.6.2 EUROPE
3.6 APPLICATION POTENTIAL
3.7 TECHNOLOGY LANDSCAPE
3.8 PIPELINE ANALYSIS
3.9 PORTER'S ANALYSIS
3.10 PESTEL ANALYSIS
CHAPTER 4 COMPETITIVE LANDSCAPE, 2022
4.1 INTRODUCTION
4.2 COMPANY MATRIX ANALYSIS, 2022
4.3 COMPETITIVE ANALYSIS OF MAJOR MARKET PLAYERS
4.4 COMPETITIVE POSITIONING MATRIX
4.5 STRATEGY DASHBOARD
4.6 STRATEGY OUTLOOK MATRIX
CHAPTER 5 ANTI-INFLAMMATORY DRUGS MARKET SIZE AND FORECAST, BY DRUG CLASS 2025-2033
5.1 KEY TRENDS, BY DRUG CLASS
5.2 ANTI-INFLAMMATORY BIOLOGICS
5.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.4 CORTICOSTEROIDS
5.5 OTHER DRUG CLASS
CHAPTER 6 ANTI-INFLAMMATORY DRUGS MARKET SIZE AND FORECAST, BY TREATMENT 2025-2033
6.1 KEY TRENDS, BY TREATMENT
6.2 ARTHRITIS
6.3 INFLAMMATORY BOWEL DISEASE (IBD)
6.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
6.5 MULTIPLE SCLEROSIS
6.6 OTHER TREATMENTS
CHAPTER 7 ANTI-INFLAMMATORY DRUGS MARKET SIZE AND FORECAST, BY ROUTE OF ADMINISTRATION 2025-2033
7.1 KEY TRENDS, BY ROUTE OF ADMINISTRATION
7.2 ORAL
7.3 INJECTION
7.4 TOPICAL
7.5 INTRANASAL
CHAPTER 8 ANTI-INFLAMMATORY DRUGS MARKET SIZE AND FORECAST, BY SALES CHANNEL 2025-2033
8.1 KEY TRENDS, BY SALES CHANNEL
8.2 PRESCRIPTION
8.3 OVER THE COUNTER (OTC)
CHAPTER 9 ANTI-INFLAMMATORY DRUGS MARKET SIZE AND FORECAST, BY REGION 2025-2033
9.1 KEY TRENDS, BY REGION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 SPAIN
9.3.5 ITALY
9.3.6 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 BRAZIL
9.5.2 MEXICO
9.5.3 ARGENTINA
9.5.4 REST OF LATIN AMERICA
9.6 MEA
9.6.1 SOUTH AFRICA
9.6.2 SAUDI ARABIA
9.6.3 REST OF MEA
CHAPTER 10 COMPANY PROFILES
10.1 ABBVIE INC.
10.2 MERCK & CO., INC.
10.3 BRISTOL-MYERS SQUIBB COMPANY
10.4 JOHNSON & JOHNSON SERVICES, INC.
10.5 PFIZER INC.
10.6 NOVARTIS AG
10.7 GLAXOSMITHKLINE PLC.
10.8 ELI LILLY AND COMPANY
10.9 AMGEN INC.
10.10 BIOGEN
10.11 OTHERS
著作権 ©2022 無断複写・転載を禁じます
